VPN Plus+ ExclusiveLess Fear, More Hope: How Research is Driving New Strategies in Hemangiosarcoma Treatment and PreventionDecember 11, 2025In this session: Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, enlightens attendees with original research from the University of Minnesota on eBAT, a first-in-class bispecific targeted angiotoxin. eBAT is designed to selectively eliminate tumor cells and tumor-initiating cells, offering dual potential as both a therapeutic and preventive option in high-risk canine populations.
Education Center - SponsoredRethinking Our Approach to Canine OA: Treating synovial inflammationby • Exubrion TherapeuticsIt’s time to reframe arthritis not just as a painful condition, but as a disease of rampant synovial inflammation. In adopting a proactive treatment strategy that is aimed at modulating the inflammatory process, veterinarians can now provide more effective, long-term care.
